A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate complete molecular response of Dasatinib in patients
for Philadelphia chromosome-positive chronic myeloid leukemia
Phase:
Phase 2
Details
Lead Sponsor:
Kanto CML Study Group
Collaborator:
Epidemiological and Clinical Research Information Network